Description
Structure & Identity
Retatrutide is a synthetic peptide designed as a triple agonist across the GLP-1, GIP, and glucagon receptors, built on a GIP-derived backbone with a fatty-acid chain for extended activity. Its three-receptor reach is the defining trait; the numeral in its common labelling points to those three receptors, not to a GLP-3 receptor, which does not exist.
Research Background
Research on Retatrutide focuses on the biology of engaging three incretin-related receptors simultaneously.
- Triple agonist. Retatrutide is built to engage the GLP-1, GIP, and glucagon receptors together [PMID: 37366315].
- Foundational characterization. It was described as a triple hormone-receptor agonist [PMID: 37366315].
- Metabolic endpoints. Its activity has been studied across metabolic readouts in research populations [PMID: 42250575].
- Liver models. It has been examined in steatotic liver disease research [PMID: 38858523].
- Polyagonist context. It is compared with other incretin agonists and polyagonists [PMID: 39305981].
These describe laboratory research areas rather than approved uses, and the peptide is supplied for that work.
Specifications
| Attribute | Value |
| Chemical name | Retatrutide |
| Also Known As | (GLP-1/GIP/glucagon triple agonist) |
| CAS number | 2381089-83-2 |
| Molecular weight | ~4731 g/mol |
| Purity | ≥99% by reverse-phase HPLC |
| Length | LY3437943 |
| Identity | Confirmed by ESI mass spectrometry |
| Physical form | Lyophilized powder |
| Appearance | White to off-white solid |
| Quantity | 10 mg per vial |
| Storage | -20°C, protected from light |
| Solubility | Soluble in bacteriostatic or sterile water (gentle mixing) |
| Classification | Research use only |
Storage & Handling
Keep the unopened vial at -20°C, away from light, until needed. After you reconstitute it, store the solution at 2-8°C and use within roughly two weeks. Because this is a large peptide supplied in a sizable 20 mg quantity, aliquoting the reconstituted stock is strongly worthwhile, and the vial should reach room temperature before opening.
Quality Assurance
Retatrutide is manufactured under research-grade controls and released only after independent verification. Reverse-phase HPLC establishes purity and mass spectrometry confirms identity, with the analysis handled by third-party laboratories, including Janoshik Analytical and domestic US labs. Each batch carries its own certificate of analysis, tying the results to the material you receive.
Frequently Asked Questions
What is the Retatrutide 20 mg for?
It is a research-use-only triple GLP-1/GIP/glucagon receptor agonist supplied in a large size for research programs that need more material. It has no approved human use in this setting.
Is the 20 mg identical to the smaller sizes?
Yes, apart from the quantity of peptide. The 20 mg vial is aimed at larger-scale or higher-throughput research.
What does Retatrutide’s “triple” action refer to?
To the three receptors it activates: GLP-1, GIP, and glucagon. It is a step beyond the single- and dual-receptor incretin peptides.
Is Retatrutide a GLP-3 agonist?
No, there is no GLP-3 receptor. Retatrutide targets the GLP-1, GIP, and glucagon receptors; the “3” is sometimes misused as “GLP-3,” which is incorrect.
Is Retatrutide FDA approved?
No, it is investigational and not FDA approved. The material here is a research-use-only reference peptide and is not for human or veterinary use.
Why are the CAS and molecular weight flagged?
Because Retatrutide is a newer compound with inconsistent registry data. We mark those fields “confirm” so they are verified before going live.
How should the 20 mg vial be handled?
Freeze at -20°C, protected from light. After reconstitution for research, aliquot, refrigerate at 2-8°C, and use within about two weeks.
How is quality verified on the larger vial?
The same standard applies to every size: ≥99% purity by reverse-phase HPLC, mass-spec identity confirmation by an independent lab, and a certificate of analysis per batch.
References
- Triple-Hormone-Receptor Agonist Retatrutide for Obesity – A Phase 2 Trial. 2023. PMID: 37366315.
- Efficacy and safety of Retatrutide, a GIP, GLP-1, and glucagon receptor agonist. 2026. PMID: 42250575.
- Triple hormone receptor agonist Retatrutide for metabolic dysfunction-associated steatotic liver disease. 2024. PMID: 38858523.
